India Appeals Board Orders Fresh Review Of Pfizer's Sutent Patent
This article was originally published in PharmAsia News
Executive Summary
An India appeals board has restored Pfizer's patent for its Sutent (sunitinib) cancer drug and ordered a new Patent Office review of the matter.